Recombinant Human soluble Tumor Necrosis Factor Receptor Type I/TNFRSF1A
Catalog No.
P1281
Featured Products
Gene ID | 7132 |
Accession # | P19438 |
Source | Escherichia coli. |
M.Wt | Approximately 21.2 kDa, a single non-glycosylated polypeptide chain containing 190 amino acids. |
AA Sequence | IYPSGVIGLV PHLGDREKRD SVCPQGKYIH PQNNSICCTK CHKGTYLYND CPGPGQDTDC RECESGSFTA SENHLRHCLS CSKCRKEMGQ VEISSCTVDR DTVCGCRKNQ YRHYWSENLF QCFNCSLCLN GTVHLSCQEK QNTVCTCHAG FFLRENECVS CSNCKKSLEC TKLCLPQIEN VKGTEDSGTT |
Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-alpha mediated cytotoxicity in the L-929 cells is less than 0.05 μg/ml, corresponding to a specific activity of > 2 × 104 IU/mg in the presence of 0.25 ng/mL of rHuTNF-alpha. |
Shipping Condition | Gel pack. |
Handling | Centrifuge the vial prior to opening. |
Usage | For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 0.1 EU/μg of rHusTNF RI/TNFRSF1A as determined by LAL method.